Plain-English translation of NCT06156527 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing , a targeted cancer medication, to see if it works better when given alone or when combined with another drug called bevacizumab. The trial enrolls 120 people with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation) and a smoking history. Researchers want to know if adding bevacizumab to helps people live longer before their cancer grows.
alone is already known to help people with this type of lung cancer, but it only works for about 15 months before the cancer starts growing again. This trial is testing whether combining it with bevacizumab might extend that time to around 27 months, giving patients a longer period of benefit.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either alone or plus bevacizumab as your treatment. You will be enrolled over 18 months and then followed for at least 24 months after the last person joins the study. During this time, you will have regular clinic visits to receive your medication, have blood tests, imaging scans, and check-ins to see how the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
South Korea